The Prognostic Role of Ezrin and HER2/neu Expression in Osteosarcoma

被引:25
作者
Abdou, Asmaa G. [1 ]
Kandil, Mona [1 ]
Asaad, Nancy Y. [1 ]
Dawoud, Marwa M. [1 ]
Shahin, Ahmed A. [2 ]
Abd Eldayem, Amal F. [1 ]
机构
[1] Menofiya Univ, Fac Med, Dept Pathol, Shebein Elkom 32511, Egypt
[2] Menofiya Univ, Fac Med, Dept Orthoped, Shebein Elkom 32511, Egypt
关键词
ezrin; HER2/neu; osteosarcoma; prognosis; GROWTH-FACTOR RECEPTOR; HIGH-GRADE; GENE-EXPRESSION; CLINICAL-VALUE; OVEREXPRESSION; SURVIVAL; IMMUNOEXPRESSION; METAANALYSIS; TRASTUZUMAB; ASSOCIATION;
D O I
10.1097/PAI.0000000000000197
中图分类号
R602 [外科病理学、解剖学]; R32 [人体形态学];
学科分类号
100101 ;
摘要
Osteosarcoma is the most common primary malignant bone tumor in Egypt. Ezrin is involved in cell adhesion to the extracellular matrix and in cell-cell interactions facilitating metastasis. HER2/neu is overexpressed in breast cancer and other types of cancer. This study aimed to assess the expression of ezrin and HER2/neu in 57 primary osteosarcoma cases and to correlate their expression with the available clinicopathologic parameters and the overall, metastasis-free and event-free survival. Both ezrin and HER2/neu were not expressed in the normal bone and they were upregulated in 82.5% and 71.9% of osteosarcoma, respectively. Positive ezrin expression was significantly associated with young age (below 25 y) (P=0.01), high grade (P=0.001), and short survival time (P=0.0001). Positive HER2/neu expression was significantly associated with high-grade osteosarcoma (P=0.04). Membranous HER2/neu expression was the only factor that showed significant impact on metastasis-free (P=0.002) and event-free survival (P=0.002). Ezrin was significantly correlated with HER2/neu expression (P=0.02). Advanced stage (P=0.0001), metastasis (P=0.0001), and recurrence (P=0.01) were the factors affecting the overall survival of osteosarcoma patients. Ezrin and HER2/neu are overexpressed and coexpressed in osteosarcoma with adverse prognostic features such as high grade. Membranous pattern of HER2/neu seems to be more important than the cytoplasmic pattern because of its impact on metastasis-free and event-free survival. Therefore, ezrin and HER2/neu could be potential prognostic markers and treatment targets for osteosarcoma.
引用
收藏
页码:355 / 363
页数:9
相关论文
共 47 条
[1]   Immunohistochemical expression of ezrin in cutaneous basal and squamous cell carcinomas [J].
Abdou, Asmaa Gaber ;
Maraee, Alaa Hassan ;
El-Sayed, Eman Mostafa Mohamed ;
Elnaidany, Nada Farag .
ANNALS OF DIAGNOSTIC PATHOLOGY, 2011, 15 (06) :394-401
[2]   ErbB2 expression is correlated with increased survival of patients with osteosarcoma [J].
Akatsuka, T ;
Wada, T ;
Kokai, Y ;
Kawaguchi, S ;
Isu, K ;
Yamashiro, K ;
Yamashita, T ;
Sawada, N ;
Yamawaki, S ;
Ishii, S .
CANCER, 2002, 94 (05) :1397-1404
[3]   Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas [J].
Anninga, JK ;
van de Vijver, MJ ;
Cleton-Jansen, AM ;
Kristel, PMP ;
Taminiau, AHM ;
Nooij, M ;
Egeler, RM ;
Hogendoorn, PCW .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (07) :963-970
[4]   Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy [J].
Bacci, Gaetano ;
Ferrari, Cristina ;
Longhi, Alessandra ;
Ferrari, Stefano ;
Forni, Cristiana ;
Bacchini, Patrizia ;
Palmerini, Emanuela ;
Briccoli, Antonio ;
Pignotti, Elettra ;
Balladelli, Alba ;
Picci, Piero .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2006, 28 (12) :774-780
[5]   Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer [J].
Blok, Erik J. ;
Kuppen, Peter J. K. ;
van Leeuwen, Jeroen E. M. ;
Sier, Cornelis F. M. .
CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2013, 7 :41-51
[6]   Immunoexpression of Ezrin and CD44 in Patients With Osteosarcoma [J].
Boldrini, Erica ;
Peres, Stela Verzinhasse ;
Morini, Sandra ;
de Camargo, Beatriz .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2010, 32 (06) :E213-E217
[7]   P-glycoprotein binds to ezrin at amino acid residues 149-242 in the FERM domain and plays a key role in the multidrug resistance of human osteosarcoma [J].
Brambilla, Daria ;
Zamboni, Silvia ;
Federici, Cristina ;
Lugini, Luana ;
Lozupone, Francesco ;
De Milito, Angelo ;
Cecchetti, Serena ;
Cianfriglia, Maurizio ;
Fais, Stefano .
INTERNATIONAL JOURNAL OF CANCER, 2012, 130 (12) :2824-2834
[8]   Correlation of the Rac1/RhoA Pathway With Ezrin Expression in Osteosarcoma [J].
Chiappetta, Caterina ;
Leopizzi, Martina ;
Censi, Fabiana ;
Puggioni, Chiara ;
Petrozza, Vincenzo ;
Rocca, Carlo D. ;
Di Cristofano, Claudio .
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2014, 22 (03) :162-170
[9]   Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group [J].
Ebb, David ;
Meyers, Paul ;
Grier, Holcombe ;
Bernstein, Mark ;
Gorlick, Richard ;
Lipshultz, Steven E. ;
Krailo, Mark ;
Devidas, Meenakshi ;
Barkauskas, Donald A. ;
Siegal, Gene P. ;
Ferguson, William Shay ;
Letson, George Douglas ;
Marcus, Karen ;
Goorin, Allen ;
Beardsley, Peter ;
Marina, Neyssa .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (20) :2545-2551
[10]   Prognostic significance of rnrnunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma [J].
Ferrari, Stefano ;
Zanella, Licciana ;
Alberghini, Marco ;
Palmerini, Emanuela ;
Staals, Eric ;
Bacchini, Patrizia .
PEDIATRIC BLOOD & CANCER, 2008, 50 (04) :752-756